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Abstract 
Purpose: Quality of life (QoL) is greatly impaired in major depressive disorder (MDD). These impairments 
are not fully accounted for by symptom severity, may persist beyond depressive episodes, and are a risk 
factor for poor outcomes. MDD is often associated with prominent neuroendocrine changes and 
increased risk of chronic disease. However, there is a lack of research examining whether biological 
factors are related to QoL in MDD. This research examined relationships between cortisol, oxytocin, 
symptom severity, and QoL in MDD. 
Methods: Sixty adults meeting DSM-5 criteria for MDD and 60 healthy controls provided morning plasma 
samples which were analysed for cortisol and oxytocin levels, and completed measures of QoL and 
psychopathology. 
Results: Participants with MDD had lower QoL than controls. Cortisol correlated negatively with overall 
QoL and all QoL domains. Oxytocin correlated positively with overall QoL, and Psychological and Social-
Relationships domains. Additionally, cortisol levels were inversely related to psychological QoL, and 
oxytocin was positively related to social QoL, after controlling for symptom severity and demographic 
variables. 
Conclusions: This study provides novel evidence linking neuroendocrine pathways to particular domains 
of QoL in MDD. The results indicate that activity of the hypothalamic-pituitary-adrenal axis is linked to 
poor psychological QoL, and that oxytocin is important to social QoL, independently of severity of 
psychopathology. Biopsychosocial approaches to QoL associated with mental health conditions may lead 
to greater understanding of the underlying mechanisms and to improved, tailored interventions. 
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Abstract  
Purpose:  
Quality of life (QoL) is greatly impaired in major depressive disorder (MDD). These 
impairments are not fully accounted for by symptom severity, may persist beyond depressive 
episodes and are a risk factor for poor outcomes. MDD is often associated with prominent 
neuroendocrine changes and increased risk of chronic disease. However, there is a lack of 
research examining whether biological factors are related to QoL in MDD. This research 
examined relationships between cortisol, oxytocin, symptom severity, and QoL in MDD.  
Methods: 
Sixty adults meeting DSM-5 criteria for MDD and 60 healthy controls provided morning 
plasma samples which were analysed for cortisol and oxytocin levels, and completed 
measures of QoL and psychopathology.  
Results: 
Participants with MDD had lower QoL than controls. Cortisol correlated negatively with 
overall QoL and all QoL domains. Oxytocin correlated positively with overall QoL, and 
Psychological and Social-Relationships domains. Additionally, cortisol levels were inversely 
related to psychological QoL, and oxytocin was positively related to social QoL, after 
controlling for symptom severity and demographic variables.  
Conclusions: 
This study provides novel evidence linking neuroendocrine pathways to particular domains of 
QoL in MDD. The results indicate that activity of the hypothalamic-pituitary-adrenal axis is 
linked to poor psychological QoL, and that oxytocin is important to social QoL, 
independently of severity of psychopathology. Biopsychosocial approaches to QoL 
associated with mental health conditions may lead to greater understanding of the underlying 
mechanisms and to improved, tailored interventions. 
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Introduction  
Quality-of-life (QoL) is increasingly recognised as an important consideration in 
mental health care and research. While the complex determinants are still unclear, the 
interaction of distress factors such as psychopathology and protection factors including 
physical health and social relationships contribute to QoL [1]. The WHO definition of QoL 
incorporates the individual’s cultural, social and environmental context and addresses 
specific domains including health, work, family, social relationships and leisure activities [2]. 
People with major depressive disorder (MDD) report much lower QoL relative to 
non-depressed people and also those with chronic medical conditions including cancer, 
hypertension, diabetes and chronic pain [3]. Additionally, individuals with MDD suffer from 
poor QoL even after reduction of symptom severity during treatment, and poor QoL may 
predict further depressive episodes [4]. QoL is therefore considered important in the 
assessment and treatment of MDD, and is viewed as the ultimate outcome measure of 
treatment success [4]. The relationship of QoL to MDD has received little attention relative to 
other mental disorders [1, 4].  
Clinically-depressed individuals may report poorer QoL due to distress associated 
with negative thinking and low mood which are core depressive symptoms. Depressive 
symptoms and poor QoL, however, are not synonymous [4]. Previous research indicates that 
QoL is not the opposite of depression; there are only weak-moderate correlations between 
depressive symptoms and QoL [5] and depressive symptoms only explain around a quarter to 
a third of variance in QoL [4]. QoL is therefore multi-dimensional and only partly 
attributable to depressive symptoms [4]. Further research is needed to understand which 
factors in addition to clinical symptom severity, particularly biological factors, are associated 
with poor QoL in MDD [3, 4, 6], with a view to improving interventions [3, 7]. 
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The burden of MDD extends beyond psychosocial functioning to somatic health, with 
MDD being associated with increased risk of cardiovascular and diabetic morbidity and 
mortality. Prominent neuroendocrine changes are reported in MDD, including dysregulation 
of the hypothalamic-pituitary-adrenal (HPA) axis and cortisol secretion [8], which is 
hypothesised to underpin the links with these chronic health comorbidities [9]. There is also 
evidence from several studies that the oxytocin system is altered in MDD [10, 11]. The 
neuropeptide oxytocin is involved in regulating complex social behaviour, anxiety, and HPA 
axis physiology in mammals [12, 13], all of which are related to MDD. These biological 
correlates may be associated with the variance of QoL measures in MDD that are not 
explained by depressive symptoms alone.  
Cortisol is a glucocorticoid hormone which plays a vital role in stress responses and 
the progression of MDD [14]. Cortisol synthesis and release from the adrenal cortex is 
primarily controlled by the HPA axis [15]. Cortisol regulates stress responses through the 
inhibition of the HPA axis via negative feedback mechanisms in the hippocampus [16], and 
additionally regulates functions such as neurogenesis, metabolism, immune responses, 
memory formation, and diurnal sleep patterns [17]. 
Disturbances in HPA axis function are reliably found in psychiatric disorders [18] and 
may partially mediate the relationship between stress and psychiatric disorders [19]. Cortisol 
is often correlated with psychopathology, stress and negative affect [20], and epidemiological 
studies have found that cortisol output in healthy populations is inversely correlated with 
positive wellbeing [21]. Additionally, a substantial literature has identified elevated cortisol 
levels [22] or dysregulated cortisol release [23] in MDD. 
Few studies have examined relationships between cortisol and QoL, particularly in 
MDD. Knuth, Cocco [24] reported that, among health professionals, salivary cortisol was 
inversely related to Environmental-QoL; but not to depression. Carlson, Speca [25] found 
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that improvement in QoL was associated with reduced afternoon cortisol levels in cancer 
outpatients; but no relationship between depressive symptoms and cortisol. In patients with 
functional somatic syndromes, Mutsuura, Kanbara [26] found inverse correlations between 
morning salivary cortisol and depressive scores, and positive correlations between cortisol 
and psychological-QoL, however controls showed the reverse pattern. Further examination of 
these relationships, including interactions with other hormones, such as oxytocin, which 
attenuates HPA activity, is needed to understand relationships between neuroendocrine 
markers and QoL. 
Oxytocin is synthesised in the hypothalamus, projected into other brain regions and 
released into the bloodstream where it has peripheral effects. Oxytocin is increasingly 
recognised as a key regulator in many complex social behaviours, and is implicated in mental 
disorders that involve impaired social interactions including schizophrenia, autism, and MDD 
[27]. Blunted oxytocin functioning has been associated with reduced attachment, trust and 
social support-seeking behaviours [e.g. 20]. It may therefore be associated with impaired 
social QoL seen in MDD. Oxytocin also regulates neuroendocrine stress responses [28] and 
promotes social approach behaviour [20]; which may improve QoL. To our knowledge, no 
study has examined relationships between oxytocin and QoL in MDD. Given that oxytocin is 
important to emotionality, stress coping and complex social interactions, which shape our 
personality and mental health [29], it is reasonable to predict that it will be related to QoL in 
MDD. 
 
Aims and Hypotheses 
Understanding relationships between biological factors and QoL is necessary to 
understand how to improve function and wellbeing in MDD. There is a scarcity of 
research in this area, and to the best of the authors’ knowledge, no previous research 
has examined whether these neuroendocrine measures predict QoL in MDD. This 
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study therefore addressed the following research questions, which have yet to be 
answered by the existing body of research. 
1. Are markers of neuroendocrine activity, specifically plasma cortisol and oxytocin 
concentrations, related to QoL in MDD? 
2. Do the different domains of QOL show differential relationships with cortisol and 
oxytocin? 
3. Are cortisol and oxytocin associated with decrements in QoL in MDD beyond that 
explained by demographics and severity of psychopathology symptoms including 
those of depression and other disorders?  
It was hypothesised that: 
1. Cortisol levels will be negatively related to overall QoL and oxytocin levels will 
be positively related to overall QoL. 
2. Cortisol will be inversely related to psychological and physical domains of QoL 
and oxytocin will be positively related to the social relationships domain of QoL.  
3. Cortisol and oxytocin will account for unique variance in QoL in MDD, after 
controlling for age, sex and severity of psychopathology symptoms including 
depression. 
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Method  
Participants 
We recruited 120 participants (60 adults meeting DSM-5 diagnostic criteria for MDD 
and 60 healthy controls, 67 females, 53 males) aged between 18 and 69 years of age (M = 
32.14, SD = 12.92). The sample size was selected on an a-priori basis based on power 
calculations and previous research. Using the G*Power statistical tool, version 3.1.9.4 [30], to 
achieve a statistical power of 80% with significance at p <.05, for two-tailed correlations with 
a medium effect size (.03), a total of 84 participants is required.  For linear multiple 
regression examining R2 increase, with a medium effect size (.15) and five predictor 
variables, a sample size of 92 participants is required [30]. Participants were recruited 
through local advertisements which were placed online and around the university campus. 
Details of the study requirements and inclusion and exclusion criteria were given to people 
making contact, and those who were interested were thoroughly screened prior to 
participation to ensure they were suitable. The MDD group consisted of 32 females and 28 
males, aged between 18 and 69 years of age (M = 31.90, SD = 14.55). The control group 
consisted of 35 females and 25 males, aged between 20 and 60 years of age (M = 31.83, SD = 
10.98).  
Inclusion criteria required that participants with MDD were not receiving any 
pharmacological or psychological treatment for depression. Controls did not have any history 
of significant mental health problems or diagnosed mental disorders. Further, exclusion 
criteria across both groups included neurological illness, substance use disorders, and use of 
corticosteroid medications. Participants received a store voucher to compensate them for their 
time and inconvenience. The study was part of a larger study into health in MDD and the 
protocol has been previously reported [31]. The cortisol and oxytocin levels have also been 
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previously reported in relation to different psychometrics and research questions; participants 
with MDD had higher plasma cortisol and lower plasma oxytocin levels than controls [31]. 
Materials 
The WHOQOL-BREF was chosen as a valid and brief measure of QoL which is 
suitable for use in healthy and clinical populations [2]. It is a 26-item self-report scale that 
measures perceived QoL across four domains: Physical-Health, Psychological-Health, 
Social-Relationships, and Environment [32], with higher scores connoting higher QoL. The 
Physical-Health domain comprises facets such as energy and fatigue. The Psychological-
Health domain comprises facets such as feelings and thoughts. The Social-Relationships 
domain comprises facets such as personal relationships and social support. The 
Environmental domain comprises facets such as physical safety and security. The mean score 
of items within each domain is used to calculate a domain score. Each domain score is then 
multiplied by 4 in order to make domain scores comparable with the scores used in the 
WHOQOL-100 on a 0-100 scale. Additionally, an individual’s Overall QoL life is assessed 
through the first question of the WHOQOL-BREF, which asks them to rate their global QOL, 
with a possible range of scores from 1-5. The four domain scores yielded by the WHOQOL-
BREF correlated highly from .89 (Social-Relationships) to .95 (Physical-Health) with that of 
its longer form, WHOQOL-100, demonstrating good validity, consistency, and test-retest 
reliability [2].  
The Brief Symptom Inventory (BSI) is a 53-item self-report inventory that measures 
psychological symptoms of most mental disorders including depressive symptoms [33]. The 
BSI was chosen as it measures severity of and distress associated with depression and other 
psychopathology more broadly, which may be related to QoL. Respondents indicate the 
degree to which they were distressed by various psychological symptoms over the past week, 
with responses ranging from 0 (not at all) to 4 (extremely). Higher scores connote higher 
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levels of distress. The BSI profile produces three global indices of distress and nine symptom 
dimensions [33]. The three global indices of distress, designed to capture the range and 
intensity of past and present psychopathology, include: Global Severity Index (GSI), that 
provides a composite score of psychopathology; Positive Symptoms Total Index (PSTI), that 
reflects the number of symptoms experienced; and Positive Symptoms Distress Index (PSDI), 
measures the intensity of psychopathology symptoms. The different symptom dimensions on 
the BSI are highly correlated within the range of .92 to .99 with that of its longer parent 
instrument, Symptom Checklist-90-Revised (SCL-90-R) [34]. 
Procedure 
The University of Wollongong ethics committee approved the protocol in accordance 
with the Australian National Statement for the Ethical Conduct of Research, and all 
participants provided informed written consent. Participants were screened prior to attending 
to ensure they met inclusion and exclusion criteria. Participants attended a single visit at the 
university clinical trials unit. Those in the MDD group were interviewed using the Mini 
International Neuropsychiatric Interview [35], a semi-structured interview (version 7.0.2) 
based on DSM-5 diagnostic criteria, to confirm that they met diagnostic criteria for MDD. All 
participants completed psychometric measures. A phlebotomist drew 8ml of blood from the 
antecubital vein into an EDTA (ethylenediaminetetraacetic acid) tube with aprotinin (enzyme 
inhibitor). All blood samples were taken between 9am and 11am. Further measures that are 
not included here were taken as part of the larger program of research into physical health in 
MDD. The whole procedure took approximately one hour. 
Biological sample collection and analysis. Blood samples were stored on ice until 
centrifuged for 10 mins at 2800rpm and 4oC, and then plasma stored at -80 oC until analysis. 
Plasma concentrations of oxytocin and cortisol were analysed using an ELISA kit (Abcam), 
with absorbance detection at 450nm.  For oxytocin analysis, samples were initially extracted 
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with acetonitrile and then measured in duplicate, with a limit of detection of 2 ng/ml for 
cortisol and 15 pg/ml for oxytocin.  
Statistical analyses. Data were analysed using the Statistical Package for Social 
Sciences (SPSS), Version 21, with an alpha level of p <.05. Raw cortisol and oxytocin values 
were log transformed prior to analyses, to better approximate normal distributions. Chi square 
was used to compare sex distributions, and one-way analysis of variance (ANOVA) was used 
to compare ages, between groups.  
A multivariate analysis of covariance (MANCOVA) was conducted to examine the 
effects of Depression status (MDD, healthy controls) on QoL domains (Physical-Health, 
Psychological-Health, Social-Relationships, and Environment; measured by WHOQOL-
BREF). Age and sex were included as covariates. 
As the assumption of univariate normality was violated for all variables, except for 
Overall-QoL, Physical-Health and Environment domains in WHOQOL-BREF, non-
parametric Spearman’s rho two-tailed correlations were conducted to investigate 
relationships between QoL and hormones. The seven variables were oxytocin, cortisol, 
Overall-QoL and the four domains of QoL.  
To investigate whether cortisol and oxytocin levels explained unique variance in 
Overall-QoL and domain-specific QoL (measured by WHOQOL-BREF), beyond that 
accounted for by demographic variables and severity of psychopathology including 
depression, five hierarchical multiple regression analyses (HMRAs) were performed. The 
dependent variables (DVs) were Overall-QoL and the four individual QoL domains. We 
included cortisol and oxytocin as the independent variables (IVs) of interest, to investigate 
their contribution to variability in overall QoL and each domain of QoL. Because symptom 
severity, sex and age may affect QoL, we included these in step 1 of each hierarchical 
regression to separately account for their contribution to QoL. The five predictors (IVs) were 
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Age, Sex, GSI (symptom severity including depressive symptoms), cortisol and oxytocin 
levels. Because this analysis was exploratory in nature, we did not correct for multiple 
comparisons in the HMRAs. 
Prior to interpretation of results, all variables were evaluated for accuracy of input, 
missing data, and violation of assumptions. The assumptions of multicollinearity, and 
assumption of linearity and homoscedasticity of residuals were all met. However, the 
assumption of multivariate outliers and homogeneity of variance-covariance matrices were 
violated. Additionally, examination of the Shapiro-Wilk statistics and histograms indicated 
some violations of normality in some of the BSI and QoL subscales. Additionally, the 
assumptions of normality, univariate and multivariate outliers for cortisol and oxytocin were 
violated. The presence of genuine outliers and non-normal distributions is commonly noted in 
hormonal research and may reflect natural variability in endogenous hormone levels [36, 37]. 
Further, MANOVA [38, 39] and linear regressions [40] have been shown to be robust to most 
violations, particularly in sample sizes over 30, and studies have shown that only severe 
violations would affect statistical inferences. Nevertheless, Log10 transformation was 
conducted on variables which were skewed. The pattern of results was equivalent between 
the non-transformed and transformed data for each part of the study. Thereafter, analyses 
were performed by removing the outliers in the non-transformed data. As the significant 
effects were equivalent to the analysis prior to their removal, the outliers were retained and 
analyses with the outliers are reported. 
Results 
Descriptive statistics and reliability values are presented in Table 1. The Cronbach’s 
alpha values for all measures and subscales exceeded .70, indicating acceptable internal 
consistency. The MDD and control groups did not differ significantly on age, F (1, 118) 
= .036, p = .850. or sex distribution, X2 (2, N = 120) = 0.22, p = 0.72. 
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The MANCOVA indicated that after controlling for age and sex, the main effect of 
Depression group (MDD, Control) on QoL was significant, Λ = .47, F (5, 114) = 25.65, p 
< .001, partial ƞ2 = .53. Age was a significant covariate, Λ = .77, F (5, 114) = 6.89, p < .001, 
partial ƞ2 = .23. The main effect of sex was not significant, Λ = .97, F (5, 114) = .66, p = .65, 
partial ƞ2 = .03. There were no significant interaction effects. Table 2 presents the between-
subject effects. Depressed individuals reported significantly lower QoL in all domains than 
controls (Table 1).  
Correlational results for all participants in both MDD and control groups are 
presented in Table 3. Cortisol correlated negatively with Overall-QoL and all four domains. 
Oxytocin correlated positively with Overall-QoL, Psychological-Health QoL, and Social-
Relationships QoL. Correlational analyses were also conducted separately for the MDD and 
control groups. These showed similar patterns to the combined group correlations, however 
there were fewer significant correlations due to the reduced power. For correlations, to detect 
medium effect sizes with .05 alpha, 84 participants are needed to achieve 80% power [30], 
hence the analysis by single group was underpowered. We have therefore reported the results 
for the combined groups. 
Results of the hierarchical multiple regression analyses (HMRAs) and regression 
statistics are presented in Tables 4 and 5. The first HMRA investigated the relative 
contribution of cortisol and oxytocin to variance in Overall-QoL, controlling for Age, Sex, 
and Global Severity Index (GSI), a measure of the severity of psychopathology symptoms, 
including depression. At step 1, Age, Sex, and GSI were entered, accounting for a significant 
44% of the variance in Overall-QoL, p < .001. At step 2, cortisol and oxytocin were added to 
the regression equation, and explained a non-significant additional 2% of the variance in 
Overall-QoL, p = .22. Collectively, the five independent variables (IVs) explained 46% of the 
variance in Overall-QoL, p < .001. Table 4 indicates that, at step 2, Age and GSI were 
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significantly associated with Overall-QoL, with GSI being the strongest predictor, β = -.60, p 
< .001. B indicated that a one unit increase in psychopathology was associated with a .7 unit 
decrease in overall QoL, and β indicated that a one SD increase in psychopathology (GSI) 
was associated with a .6 SD decrease in overall QoL, other variables being held constant. 
The second HMRA indicated that at step 1, Age, Sex, and GSI accounted for a 
significant 33% of the variance in Physical-Health QoL, p < .001. At step 2, cortisol and 
oxytocin were added, explaining an additional non-significant 3% of the variance in 
Physical-Health QoL, p = .114. Collectively, the five IVs explained 35% of the variance in 
Physical-Health QoL, p < .001. At step 2, only GSI was significantly related to Physical-
Health QoL, β = -.55, p < .001, with each SD increase in GSI yielding a .55 SD decrease in 
Physical QoL, with other variables being held constant (Table 5). 
In the next HRMA, Age, Sex, and GSI together accounted for a significant 54% of the 
variance in Psychological-Health QoL, p < .001. At step 2, cortisol and oxytocin were added, 
significantly improving the model and explaining an additional 2.4% of the variance in 
Psychological-Health QoL, p = .047. Collectively, the five IVs explained 57% of the variance 
in Psychological-Health QoL, p < .001. At step 2, GSI, β = -.64, p < .001, and cortisol, β = 
-.16, p = .029, were significant predictors of Psychological-Health QoL, with one SD of 
increase in the predictors being associated with a .64 and .16 SD decrease in Psychological 
QoL, respectively, other variables being held constant (Table 5). 
For Social-Relationships QoL, Age, Sex, and GSI initially accounted for a significant 
34% of variance, p < .001. The addition of cortisol and oxytocin significantly improved the 
model, explaining an additional 3.5% of the variance in Social-Relationships QoL, p = .048. 
Collectively, the five IVs explained 37% of the variance in Social-Relationships QoL, p 
< .001. At step 2, GSI, β = -.49, p < .001, and oxytocin, β = .17, p = .031, were significantly 
associated with Social-Relationships QoL (Table 5). Each SD increase in GSI was associated 
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with a .49 SD decrease in Social QoL, and each SD increase in oxytocin yielded a .17 SD 
increase in Social QoL, holding other variables constant. 
For Environmental-QoL, Age, Sex, and GSI initially accounted for a significant 41% 
of the variance, p < .001. Adding cortisol and oxytocin explained a non-significant additional 
1% of the variance in Environmental-QoL, p = .35. Collectively, the five IVs explained 42% 
of the variance in Environmental-QoL, p < .001. At step 2, only GSI was significantly 
associated with Environmental-QoL, β = -.58, p < .001, with each SD increase in GSI 
yielding a .58 SD decrease in Environmental-QoL (Table 5). 
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Discussion   
As hypothesised, clinically depressed individuals reported lower QoL in all domains 
than non-depressed individuals, after controlling for demographic variables, and QoL was 
inversely correlated to intensity of psychopathology symptoms. These findings are consistent 
with past studies [41-43]. MDD is a highly debilitating condition which involves a complex 
interaction of psychological, biological, social, and environmental factors, thus it is 
unsurprising that individuals with MDD show broad impairments in QoL. Additionally, the 
participants with MDD had significantly higher levels of psychopathology severity than the 
healthy controls, which were comparable to outpatient norms [44].  
To the authors’ knowledge, our study is the first to show that neuroendocrine markers 
are related to QoL in MDD. We predicted that cortisol levels would be inversely related to 
psychological and physical domains of QoL. Firstly, in bivariate analyses which did not 
adjust for other variables, cortisol levels were broadly and inversely correlated with overall 
QoL and all domains of QoL. Although there is a lack of comparable research focussed on 
MDD, the current finding is consistent with some past research that reported an inverse 
relationship between salivary cortisol and environmental QoL in health professionals [24], 
and afternoon cortisol levels and QoL in cancer outpatients [25].  
 Cortisol regulates a wide variety of functions in the body related to physical and 
mental health, such as immune responses, memory formation, and diurnal sleep patterns [17], 
and can influence individuals’ physical and psychosocial responses through stress-related 
pathologies [45]. It is therefore not surprising that cortisol levels correlated broadly with all 
domains of QoL. The current findings of inverse relationships between cortisol and QoL 
provide new information about links between neuroendocrine functioning and QoL in MDD. 
Hyperactivity of the HPA axis, indexed by elevated cortisol levels, is often reported in MDD 
[46], and may be a factor accounting for QoL impairments in depression.  
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It was predicted that oxytocin would be positively related to the social relationships 
QoL domain. In the bivariate analyses, oxytocin was correlated with overall, social and 
psychological QoL. Although there is a lack of prior research examining oxytocin and QoL in 
MDD, the present findings are consistent with studies reporting lower plasma oxytocin levels 
in patients with fibromyalgia with depressive symptoms [47], and in adults facing 
psychological distress [48]. Oxytocin has been linked to aspects of social functioning in 
mental disorders including MDD [27, 49]. The current findings, combined with previous 
research, are consistent with the possibility that oxytocin plays a two-fold role in QoL: social 
approach behaviour, and anti-stress function [48]. Oxytocin may enhance prosocial behaviour 
by reducing negative mood and stress, establishing a calmer state [50], thus facilitating social 
proximity and support [20], which are protective against MDD [48]. The role of oxytocin in 
regulating HPA axis activation and anxiety [12] is consistent with its positive correlation with 
psychological QoL in the current study.  
We also investigated the extent to which cortisol and oxytocin accounted for unique 
variance in QoL in MDD, after controlling for demographic factors and severity of 
psychopathology including depressive symptoms. In the regression analyses, we found that 
severity of psychological symptoms accounted for a significant amount of variance in all 
types QoL, congruent with prior research [6]. Additionally, cortisol accounted for unique 
variance in psychological QoL, beyond that accounted for by demographics and 
psychopathology including depressive symptoms. Although significant, the amount of 
variance explained by cortisol was small, once the strong relationship between QoL and 
psychopathology had been accounted for. Glucocorticoids are known to be neurotoxic in 
some circumstances [51] and prolonged HPA hyperactivity is associated with cognitive 
impairment [52], social withdrawal behaviour and mood changes [51]. Additionally, QoL and 
functional impairments in MDD often persist beyond depressive symptoms [53]. Further 
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research may help to understand whether direct links between cortisol and QoL may help to 
explain why QoL impairments may persist after recovery from depressive symptoms.    
 Cortisol did not significantly account for unique variance in physical QoL, after 
accounting for psychopathology. A possible explanation could be due to the the range of 
different items that are included in WHOQOL-BREF Physical-Health subscale, such as 
dependence on medical aid, which may not be directly related to cortisol levels. As this is one 
of the first studies examining biomarkers and QoL, future research looking at mechanisms 
and associations between cortisol and QoL is needed. Nevertheless, cortisol uniquely 
accounted for variance in psychological QoL beyond that accounted for by psychopathology, 
suggesting its importance to QoL in MDD.  
Oxytocin levels accounted for unique variance in social relationships QoL beyond 
that accounted for by demographics and symptom severity. This was consistent with our 
predictions, as oxytocin mediates complex social behaviours including trust, proximity and 
social support [e.g. 20]. The results suggest that higher levels of oxytocin are directly 
associated with higher perceived quality of life in terms of social relationships.   
Taken together, these findings suggest that, in bivariate analyses, cortisol is negatively 
related to all domains of QoL and oxytocin is positively related to social and psychological 
QoL. When controlling for other variables, cortisol accounts for unique variance in 
psychological QoL, and oxytocin accounts for unique variance in social QoL above that 
accounted for by intensity of psychopathology symptoms. The results provide new 
indications that individual domains of QoL are differentially associated with markers of 
neuroendocrine functioning. Additionally, they provide new information about physiological 
mechanisms associated with individuals’ subjective experience in terms of their self-rated 
satisfaction with life. Further research is needed to understand if physiological mechanisms 
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may help to explain relationships between residual poor QoL and increased risks of relapse in 
MDD.  
Implications 
The findings about the biological correlates of QoL may help to guide tailored 
approaches to assessment and interventions for MDD. In particular, poor QoL in MDD is 
related to neuroendocrine changes associated with HPA axis activity and cortisol release. 
Additional associations with activity of the oxytocin system are also of interest. It is 
important to note that the findings from this study cannot be used to determine cause-and-
effect relationships. Rather, the results suggest that there are some associations between 
cortisol, oxytocin, and QoL which persist when controlling for symptom severity. Future 
research should consider the implementation of longitudinal methods, to examine possible 
causal pathways. Nevertheless, these biological factors may show potential as modifiable 
variables which could be targeted in adjunctive interventions. For example, there is some 
evidence that cortisol levels are modifiable by diet [54] relaxation training [55] and 
mindfulness-based interventions [56]. Intra-nasal oxytocin can improve symptoms in 
psychiatric conditions involving social withdrawal including depression and is considered a 
promising adjunctive psychiatric treatment [29], however there is still a lack of adequate 
trials of oxytocin in MDD [11].  
Limitations and Future Directions 
Some limitations of the current research warrant attention. Firstly, the cross-sectional 
and correlational nature of this research precludes interpretations of causal relationships 
between QoL, hormones and psychopathology. Cortisol and oxytocin measures were taken at 
a single time point and thus provide only a cross-sectional indication of activity associated 
with activity of the HPA and oxytocin axes. Cortisol shows complex diurnal variations which 
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may be further affected in MDD, and future studies using more complex, longitudinal 
collection protocols may further elucidate cortisol-QoL relationships in MDD.  
Cortisol and oxytocin levels uniquely accounted for a significant but small variance in 
QoL above symptom severity, and much variance remains unaccounted for. Future research 
is needed into other biological and psychosocial factors, for example personality traits, which 
could act as perpetuating or protective factors in relation to QoL in MDD.  
Additionally, there may be a self-selection-bias for people who participate in research. 
Because of the heterogeneity of MDD, further research with larger sample sizes is necessary 
to confirm the findings. Therefore, the findings from this research should be considered in 
light of these limitations. Nonetheless, these are common limitations in similar research [57]. 
Conclusion 
We conducted a novel study of relationships between biomarkers and QoL in MDD. 
Major findings were that cortisol levels inversely correlated with all aspects of QoL, whereas 
oxytocin levels correlated with overall, social and psychological QOL. Additionally, cortisol 
explained unique variance in psychological QoL, and oxytocin in social QoL, above that 
accounted for by psychopathology, suggesting that each hormone is linked to specific 
domains of QoL. Further research examining biopsychosocial factors related to QoL in MDD 
may help to better understand and address the burden of this debilitating condition.  
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Table 1 
Psychometric Properties of the Study Variables by Groups 






































































Psychological Health 120 48.08 
(10.8) 
40.8 (8.56) 55.88 
(6.84) 
.89 







Environment 120 57 
(11.52) 
51.56 (8.01) 62.76 
(8.6) 
.84 
Overall QoL 120 3.59 
(1.03) 
3 (.93) 4.2 (.74) .95 
Note. n = number of responses; M = mean; SD = standard deviation. BSI = Brief Symptom 




CORTISOL, OXYTOCIN AND QUALITY OF LIFE IN DEPRESSION 25 
Table 2 
 
Summary of MANCOVA Results for Quality of Life Between Groups (Clinically Depressed 
vs. Healthy Controls), with Age and Sex as covariates.  
WHOQOL-BREF F p value Partial Eta2 
Physical Health 17.86 <.001** .13 
 Psychological Health 123.19 <.001** .51 
Social Relationships 52.25 <.001** .31 
Environment 38.47 <.001** .25 
Note. WHOQOL = World Health Organisation Quality of Life. 






























Oxytocin .25*     .00 .27* .29*        .15 
BSI 











Positive Symptoms Total -.59** -.54** -.71** -.58** -.65** 
Positive Symptoms Distress  -.53** -.53** -.68** -.44** -.56** 
Note. WHOQOL = World Health Organisation Quality of Life. 
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Table 4 
 
Summary of Hierarchical Multiple Regression Analysis Predicting Overall Quality of Life 
as Measured by WHOQOL-BREF (n = 120) 
Predictor B β sr2 p 
Step 1 R2 = .44, F (3, 116) = 30.75, p < .001 
Age -.023 -.29 .07 < .001 
Sex -.280 -.14 .02 .055 
GSI -.793 -.68 .42 < .001 
Step 2 ∆R2 = .02, ∆F (2, 114) = 1.54, p = .218 
Age -.021 -.26 .06 .001 
Sex -.236 -.11 .01 .111 
GSI -.705 -.60 .23 < .001 
Cortisol -.001 -.11 .01 .167 
Oxytocin .001 .1 .01 .178 
Total R2 = .46, adjusted R2 = .43, F (5, 114) = 19.24, p < .001 
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Table 5 
 
Summary of Hierarchical Multiple Regression Analyses Predicting the Four Domains of Quality of Life as Measured by WHOQOL-BREF (n = 120) 
 
WHOQOL-BREF 
 Physical Health Psychological Health 
 B β sr2 p B β sr2 p 
Step 1 R2 = .33, F (3, 116) = 18.73, p < .001 R2 = .54, F (3, 116) = 46.08, p < .001 
Age 0.014 0.075 0.005 0.355 -0.002 -0.008 .000 0.901 
Sex -0.093 -0.019 0.000 0.810 -0.466 -0.086 .007 0.177 
GSI -1.544 -0.545 0.270 < 0.001 -2.266 -0.739 .497 < 0.001 
Step 2 ∆R2 = .03, ∆F (2, 114) = 2.21, p = .114 ∆R2 = .024, ∆F (2, 114) = 3.15, p = .047 
Age 0.013 0.068 0.004 0.400 0.005 0.023 .000 0.733 
Sex -0.236 -0.047 0.002 0.545 -0.336 -0.062 .004 0.331 
GSI -1.559 -0.550 0.193 < 0.001 -1.953 -0.637 .259 < 0.001 
Cortisol -0.001 -0.033 0.001 0.715 -0.004 -0.162 .018 0.029 
Oxytocin -0.002 -0.154 0.021 0.055 0.002 0.107 .010 0.103 
Total R2 = .35, adjusted R2 = .32, F (5, 114) = 12.36, p < .001 R2 = .57, adjusted R2 = .55, F (5, 114) = 29.93,  p < .001 
 Social Relationships Environment 
 
B β sr2 p B β sr2 p 
Step 1 
Age 
R2 = .34, F (3, 116) = 19.52, p < .001 R2 = .41, F (3, 116) = 27.26, p < .001 
-0.035 -0.114 0.012 0.155 -0.002 -0.007 0.000 0.927 
Sex -1.027 -0.130 0.017 0.090 -0.420 -0.072 0.005 0.316 
GSI -2.635 -0.592 0.318 < 0.001 -2.120 -0.645 0.378 < 0.001 
Step 2 ∆R2 = .035, ∆F (2, 114) = 3.12, p = .048 ∆R2 = .01, ∆F (2, 114) = 1.05, p = .35 
Age -0.025 -0.081 0.006 0.313 0.003 0.011 0.000 0.882 
Sex -0.744 -0.094 0.008 0.220 -0.391 -0.067 0.004 0.360 
GSI -2.174 -0.488 0.152 < 0.001 -1.901 -0.578 0.213 < 0.001 
Cortisol -0.005 -0.147 0.015 0.099 -0.003 -0.122 0.010 0.153 
Oxytocin 0.004 0.172 0.026 0.031 0.000 0.011 0.000 0.879 
Total R2 = .37, adjusted R2 = .34, F (5, 114) = 13.39, p < .001 R2 = .42, adjusted R2 = .40, F (5, 114) = 16.79, p < .001 
Note. WHOQOL = World Health Organisation Quality of Life; GSI = Global Severity Index. 
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